Symptoms of endometrial cancer include heavy menstrual bleeding, pelvic pain, loss of appetite, nausea, abdominal pain, painful urination, and weight loss. These symptoms can develop into rectal bleeding, abdominal pain, and pelvic pain. Some patients may not experience symptoms at all.\n
around 1,700 new cases of cancer in uterine and fallopian tube were diagnosed a year in the United States. Around 2,500 new cancers in the female reproductive tract were fatal each year.
While the main source of endometrial neoplasms is benign, the incidence of early malignancy is high. The aetiology of endometrial adenocarcinoma is not yet well defined, although some risk factors may exist. The tumour develops from adenosis in only 5% of cases. It appears to be driven by the hormone-signaling axis and its imbalance. This indicates the necessity of assessing this axis in every case.
Findings from a recent study demonstrates a very high curability of adenocarcinoma, and adenomyoma. The cure rate should be investigated further and the use of adjuvant therapies to improve prognosis should be considered.
The majority of endometrial cancer is treated with surgery, chemoradiation, or hormonal therapy, while chemotherapy and other drugs are used for specific scenarios (recurrent disease, distant metastases, etc.).
It is well-documented and supported by the literature that human papillomavirus (HPV) infection is the primary cause of endometrial intraepithelial neoplasia (EIN). However, EIN lesions develop from normal intraepithelial epithelium or maybe from a metaplasia. It has also been demonstrated that endometrial carcinomas develop from endometrial intraepithelial carcinoma. Therefore, HPV may be the primary cause of endometrial carcinoma development.
We found that patients who have Gcsf were more likely to be used in combination with other treatment modalities, including radiotherapy, chemotherapy, and palliative care. The use of Gcsf plus irradiation or concurrent chemotherapy was the most common regimen. Based on our analysis of a large cohort of patients, the use of Gcsf appears not likely to substantially impact overall survival.
Women in developed countries are not at risk for developing endometrial neoplasms. However, women in developing countries are at higher risk for development of endometrial neoplasms. These data indicate that there is a difference in risk of developing endometrial neoplasms between the two groups (women in developed versus developing countries).
Clinical trials of endometrial cancer represent a valuable alternative to patient selection for adjuvant endometrial cancer treatment because they have the ability to improve overall survival for patients with endometrial cancer. We recommend consideration of clinical trials for endometrial cancers based primarily on histologic subtype and grade. ClinicalTrials.gov: http://clinicaltrials.gov/ct/show/NCT00389942(INR) "
"Terefundus ritsemae\n\nTerefundus ritsemae is a species of sea snail, a marine gastropod mollusk in the family Muricidae, the murex snails or rock snails.
When this agent was administered after surgery in this patient population, it resulted in prolongation of PFS for the whole group as well as for patients with stage IB and II uterine leiomyomas. The administration of gcfs alone also produced a significant increased PFS for the whole cohort. Recent findings support the development of a further, randomised, triple-enrovery, comparative clinical trial investigating the use of gcsf alone in uterine leiomyoma patients undergoing hysterectomy and pelvic radiotherapy.
There are no new drugs or agents that have been shown to be significantly effective in the treatment and management of endometrial neoplasms, although a few therapies have demonstrated the potential to be effective at improving survival when employed in combination with surgery and/or adjuvant therapy.